EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Personalised Long‐Term Albumin Treatment Based on Three‐Month Ascites Response in Patients With Decompensated Cirrhosis

Enrico Pompili iD, Giulia Iannone iD, Salvatore Piano, Pierluigi Toniutto iD, Antonio Lombardo, Stefania Gioia, Marta Tonon, Roberta Gagliardi iD, Daniele Carrello, Greta Tedesco iD, Vito Di Marco, Giacomo Zaccherini iD und 7 weitere

Liver International · 2026-04 · 46 (4)

DOI: 10.1111/liv.70598 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 18.03.2026. Verfasst von Enrico Pompili und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Ascites, Liver Cirrhosis, Albumins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grifols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Long‐term albumin (LTA) is effective for treating ascites in decompensated cirrhosis. This study aims to analyse the clinical courses of patients receiving LTA and provide a 3 month stratification to personalise management integrating LTA with other options.

Methods

Patients receiving LTA included in the multicentre, retrospective, observational Real‐ ANSWER study were stratified into three categories according to the response of ascites after 3 months of treatment: ‘responders’ (grade 0–1 ascites), ‘partial responders’ (at least grade 2 ascites not receiving therapeutic paracentesis) and ‘non‐responders’ (at least grade 2 ascites receiving therapeutic paracentesis). Clinical trajectories and outcomes of the different categories were compared.

Results

Of the 252 patients included (median Child‐Pugh 9, MELDNa 18), 36% were responders, 29% partial responders and 35% non‐responders. Responders differed significantly from the other groups, with higher cumulative incidence of LTA discontinuation for clinical improvement (33%) and transplantation (26%), a lower 18 month mortality (13%) and minimal use of TIPS . Partial and non‐responders showed similar trajectories with high mortality (35% and 42%) and low incidence of transplantation (12% and 11%). TIPS was performed predominantly among non‐responders (15%). Both groups had a few patients (12% and 8%) able to stop LTA for clinical improvement frequently related to an effective etiologic treatment.

Conclusions

Using a 3 month stratification according to the ascites response of LTA , patients can be grouped into three categories with different clinical courses and outcomes. This may help to stratify prognosis and inform clinical discussions on the management of ascites by integrating LTA with other available options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AscitesLiver CirrhosisAlbuminsHumansFemaleRetrospective StudiesMaleParacentesisTreatment OutcomeMiddle AgedAgedLiver TransplantationTime FactorsPrecision MedicinePortasystemic Shunt, Transjugular Intrahepatic

Stichwörter der Autor:innen

TIPSascitesparacentesisportal hypertensionrefractory ascites

Substanzen

Albumins

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Unit of Internal Medicine and Hepatology, Department of Medicine-DIMED, University and Hospital of Padova, Padua, Italy.
  • Hepatology and Liver Transplantation Unit, University Academic Hospital, Udine, Italy.
  • UOC Di Gastroenterologia, Dipartimento Di Promozione Della Salute, Materno Infantile, Medicina Interna e Specialistica (PROMISE), University of Palermo, Palermo, Italy.
  • Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

ORCID-Profile: Enrico Pompili, Giulia Iannone, Pierluigi Toniutto, Roberta Gagliardi, Greta Tedesco, Giacomo Zaccherini, Maurizio Baldassarre, Paolo Caraceni

Förderung

  • Grifols

Zitieren

APA

Pompili, E., Iannone, G., Piano, S., Toniutto, P., Lombardo, A., Gioia, S., Tonon, M., Gagliardi, R., Carrello, D., Tedesco, G., Di Marco, V., Zaccherini, G., Lani, L., Baldassarre, M., Nardelli, S., Bitetto, D., Calvaruso, V., Angeli, P., & Caraceni, P. (2026). Personalised Long‐Term Albumin Treatment Based on Three‐Month Ascites Response in Patients With Decompensated Cirrhosis. Liver International, 46(4). https://doi.org/10.1111/liv.70598

Vancouver

Pompili E, Iannone G, Piano S, Toniutto P, Lombardo A, Gioia S, et al. Personalised Long‐Term Albumin Treatment Based on Three‐Month Ascites Response in Patients With Decompensated Cirrhosis. Liver International. 2026;46(4). doi:10.1111/liv.70598

BibTeX
@article{Pompili2026,
  author = {Pompili, Enrico and Iannone, Giulia and Piano, Salvatore and Toniutto, Pierluigi and Lombardo, Antonio and Gioia, Stefania and Tonon, Marta and Gagliardi, Roberta and Carrello, Daniele and Tedesco, Greta and Di Marco, Vito and Zaccherini, Giacomo and Lani, Lorenzo and Baldassarre, Maurizio and Nardelli, Silvia and Bitetto, Davide and Calvaruso, Vincenza and Angeli, Paolo and Caraceni, Paolo},
  title = {Personalised Long‐Term Albumin Treatment Based on Three‐Month Ascites Response in Patients With Decompensated Cirrhosis},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {4},
  doi = {10.1111/liv.70598}
}
Kostenlos starten →